Pathophysiology of diabetic retinopathy

Drug News and Perspectives

Volumn 15, Issue 10, 2002, Pages 633-639

  Funatsu, Hideharu ^a   Yamashita, Hidetoshi ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOGENESIS INHIBITOR; ANGIOTENSIN; COLLAGEN; COLLAGEN TYPE 18; CYTOKINE; DIACYLGLYCEROL; ENDOSTATIN; GROWTH FACTOR; INTERLEUKIN 6; PIGMENT EPITHELIUM DERIVED FACTOR; POLYOL; PROTEIN KINASE C BETA; RENIN; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOACTIVE AGENT;

ANGIOGENESIS; ARTICLE; CLINICAL FEATURE; DIABETIC RETINOPATHY; GLYCATION; HYPERGLYCEMIA; MOLECULAR INTERACTION; NEOVASCULARIZATION (PATHOLOGY); OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0036972463     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2002.15.10.840018     Document Type: Article

References (53)

1. Klein, R., Klein, B.E.K., Moss, S.E. and Cruickshanks, K.J. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998, 105: 1801-15.
2. Alder, V.A., Su, E.N., Yu, D.Y., Cringle, S.J. and Yu, P.K. Diabetic retinopathy: Early functional changes. Clin Exp Pharmacol Physiol 1997, 24: 785-8.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329: 977-86.
4. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UPKDS 33). Lancet 1998, 352: 837-53.
5. Shichiri, M., Kishikawa, H., Ohkubo, Y. and Wake, N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000, 23(Suppl 2): B21-9.
6. Segawa, M., Hirata, Y., Fujimori, S. and Okada, K. The development of electroretinogram abnormalities and the possible role of polyol pathway activity in diabetic hyperglycemia and galactosemia. Metabolism 1988, 37: 454-60.
7. Narayanan, S. Aldose redactase and its inhibition in the control of diabetic complications. Ann Clin Lab Sci 1993, 23: 148-58.
8. Stevens, M.J., Henry, D.N., Thomas, T.P., Killen, P.D. and Greene, D.A. Aldose reductase gene expression and osmotic dysregulation in cultured human pigment epithelial cells. Am J Physiol 1993, 265: E428-38.
9. Sato, S., Secchi, E.F., Lizak, M.J. et al. Polyol formation and NADPH-dependent reductases in dog retinal capillary perycytes and endothelial cells. Invest Ophthalmol Vis Sci 1999, 40: 697-704.
10. Stevens, M.J., Dananberg, J., Feldman. E.L. et al. The linked roles of nitric oxide, aldose reductase and (Na+, K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994, 94: 853-9.
11. Vlassara. H. Recent progression in advanced glycation end products and diabetic complications. Diabetes 1997, 46(Suppl 2): S19-25.
12. Stitt, A.W., He, C. and Vlassara, H. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem Biophys Res Commun 1999, 256: 549-66.
13. Yamagishi, S.I., Yonekura, H., Yamamot, Y. et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997, 272: 8723-30.
14. King, G.L. and Brownlee, M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996, 25: 255-70.
15. Kern, T.S., Kowluru, R.A. and Engerman, R.L. Abnormalities of retinal metabolism in diabetes or galactosemia: ATPases and glutathione. Invest Ophthalmol Vis Sci 1994, 35: 2962-7.
16. Nishikawa, T., Edelstein, D., Du, X.L. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 2000, 404: 787-90.
17. Ishii, H., Jirousek, M.R., Koya, D. et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272: 728-31.
18. Shiba, T., Inoguchi, T., Sportsman, J.R., Heath, W.F., Bursell, S. and King, G.L. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993, 265: E783-93.
19. Xia, P., Inoguchi, T., Kern, T.S., Engerman, R.I., Oates, P.J. and King, G.L. Characterization of the mechanism for the chronic activation of DAG-PKC pathway in diabetes and hypergalactosemia. Diabetes 1994, 43: 1122-9.
20. Danser, A.H.J., van den Dorpel, M.A., Deinum, J. et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989, 68: 160-7.
21. Danser, A.H.J., Derkx, F.H.M., Admirral, P.J.J. et al. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994, 35: 1008-18.
22. Funatsu, H., Yamashita, H., Nakanishi, H. et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2002, 86: 311-5.
23. Funatsu, H., Yamashita, H., Ikeda, T. et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 2002, 133: 537-44.
24. Lonchampt, M., Pennel, L. and Dubault, J. Hyperoxia/normoxia-driven retinal angiogenesis in mice: A role for angiotensin II. Invest Ophthalmol Vis Sci 2001, 42: 429-32.
25. Gilbert, R.E., Kelly, D.J., Cox, A.J. et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000, 43: 1360-7.
26. van Buggenum, I.M.H., Polak, B.C.P., Reichert-Thoen, J.W.M. et al. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 2002, 45: 203-9.
27. Chaturvedi, N., Sjolie, A.K., Stephenson, J.M. et al., and the EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type I diabetes. Lancet 1998, 351: 28-31.
28. Chua, C.C., Hamdy, R.C., Chua, B.H.L. et al. Upregulation of vascular growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1998, 1401: 187-94.
29. Otani, A., Takagi, H., Suzuma, K. et al. Angiotensin potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998, 82: 619-28.
30. Aiello, L.P., Avery, R.L., Arrigg, P.G. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331: 1480-7.
31. Hammes, H.P., Lin, J.H., Bretzel, R.G. et al. Upregulation of the vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998, 47: 401-6.
32. Funatsu, H., Yamashita, H., Shimizu, E. et al. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina 2001, 21: 469-77.
33. Funatsu, H., Yanashita, H., Noma, H. et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetic macular edema. Am J Ophthalmol 2002, 133: 70-7.
34. Lutty, G.A., McLeod, D.S., Merges, C. et al. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 1996, 114: 971-9.
35. Antonetti, D.A., Barber, A.J., Khin, S. et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occladin content. Penn State Retina Research Group. Diabetes 1998, 47: 1953-9.
36. Murray, P.I., Hoekzem, R., van Haren, M.A.C. et al. Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci 1990, 31: 917-20.
37. Kauffmann, D.J.H., van Meurs, J.C., Mertens, D.A.E. et al. Cytokines in vitreous humor: Interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1994, 35: 900-6.
38. Hirano, T., Akira, S., Taga, T. and Kishimoto, T. Biological and clinical aspects of interleukin-6. Immunol Today 1990, 11: 443-9.
39. Plank, S.R., Dang, T.T., Graves, D. et al. Retinal pigment epithelium cells secrete interleukin-6 in response to interleukin-1. Invest Ophthalmol Vis Sci 1992, 33: 78-82.
40. Cubitt, C.L., Lausch, R.N. and Oakes, J.E. Differences in interleukin-6 gene expression between cultured human corneal epithelial cells and keratocytes. Invest Ophthalmol Vis Sci 1995, 36: 330-6.
41. Cohen, T., Nahari, D., Cerem, L.W. et al. Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271: 736-41.
42. Maruo, N., Morita, I., Shirao, M. and Murota, S. IL-6 increases endothelial permeability in vitro. Endocrinology 1992, 131: 710-4.
43. Hojo, Y., Ikeda, U., Maeda, Y. et al. Interaction between haman monocytes and vascalar smooth muscle cells induces vascular endothelial growth factor expression. Atherosclerosis 2000, 150: 63-70.
44. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1: 27-31.
45. Hanahan, D. and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86: 353-64.
46. Dawson, D.W., Volpert, O.V., Gillis, P. et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999, 285: 245-8.
47. Spranger, J., Osterhoff, M., Reimann, M. et al. Loss of the anti-angiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001, 50: 2641-5.
48. Mori, K., Duh, E., Gehlbach, P. et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001, 188: 253-63.
49. O'Reilly, M.S., Boehm, T., Shing, Y. et al. Endostatin. Endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88: 277-85.
50. Yamaguchi, N., Anand-Apte, B., Lee, M. et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999, 18: 4414-23.
51. Mori, K., Ando, A., Gehlbach, P. et al. Inhibition of choroidal neovascalarization by intravenous injection of adenoviral vectors expressing endostatin. Am J Pathol 2001, 159: 313-20.
52. Funatsu, H., Yamashita, H., Noma, H. et al. Stimulation and inhibition of angiogenesis in diabetic retinopathy. Jpn J Ophthalmol 2001, 45: 577-84.
53. Noma, H., Funatsu, H., Yamashita, H. et al. Regulation of angiogenesis in diabetic retinopathy: Possible balance between stimulator and inhibitor. Arch Ophthalmol 2002, 120: 1075-80.